Refeyn

Refeyn Ltd. specializes in the development, production, and distribution of mass photometry technologies for industry and academia. Mass photometry and macro mass photometry are unique bioanalytical technologies pioneered by Refeyn. By quantifying light scattering from particles in solution, mass photometry enables the measurement of molecular mass at the single-particle level while macro mass photometry enables simultaneous measurement of viral vector size and contrast (a proxy for mass). 

Spun out of Oxford University in 2018, the company aims to make its technology accessible to all in the scientific community, enabling users to achieve new and better outcomes. Refeyn has been recognized for its unique approach to biomolecular analysis through multiple awards, including the Royal Society of Chemistry Emerging Technologies Competition. Applications of mass photometry include: Characterization of samples of biomolecules and viral vectors, and analysis of protein oligomerization, biomolecular interactions, and macromolecular assemblies. Utilizing the novel technologies of mass photometry and macro mass photometry, Refeyn’s products are capable of accurate analysis of single particles in solution, in their native state, and without the need for labels, opening up new possibilities for bioanalytics.

Content by Refeyn

A 3D-rendered digital illustration of antibody molecules floating in a dark fluid environment
| 5 min read
Abstract scientific concepts with A scientist pipetting in the background
| 3 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

How new alternative methods are changing drug safety testing.
 Can animal testing be replaced? Discover how scientists are developing more human-relevant ways to predict drug toxicity earlier.
White laboratory mouse standing in a petri dish in a laboratory, illustrating a rodent model commonly used in scientific and preclinical studies.
Learn about common challenges and proper maintenance practices for catheterized rodent models.
Hand reaching toward a glowing AI head icon on a digital network interface with connected tech symbols.
Learn why data quality, governance, and collaboration are critical to realizing AI’s potential across the drug discovery pipeline.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue